Related Experiment Video
Updated: Aug 23, 2025
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.0K
Inhibition of Amyloid Protein Aggregation Using Selected Peptidomimetics
1Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad, 500007, India.
Chemmedchem
|November 1, 2022
Summary
Peptidomimetics can inhibit amyloid protein aggregation, offering a new therapeutic strategy for diseases like Alzheimer's and Parkinson's. This approach targets protein-protein interactions to develop novel anti-amyloid agents.
Area of Science:
- Biochemistry and Molecular Biology
- Drug Discovery and Development
- Neuroscience and Neurodegenerative Diseases
Background:
- Aberrant protein aggregation into amyloid fibrils is implicated in over 40 incurable diseases, including Alzheimer's, Parkinson's, type 2 diabetes, and cancer.
- Understanding the mechanisms of protein aggregation and toxicity is crucial for developing effective therapeutic interventions.
- Amyloid inhibitors are actively researched to combat these debilitating conditions.
Purpose of the Study:
- To review peptidomimetic-based strategies for modulating the aggregation of key amyloidogenic proteins.
- To highlight the potential of peptidomimetics as a therapeutic tool against amyloid-related diseases.
- To explore the application of peptidomimetics in targeting specific amyloid proteins like Islet Amyloid Polypeptide, Amyloid Beta, α-synuclein, mutant p53, and insulin.
Main Methods:
- Literature review of peptidomimetic approaches targeting protein-protein interactions (PPIs).
- Focus on studies modulating the aggregation of specific amyloid proteins: Islet Amyloid Polypeptide (IAPP), Amyloid Beta (Aβ), α-synuclein, mutant p53, and insulin.
- Analysis of how peptidomimetics interfere with the formation of amyloid fibrils.
Main Results:
- Peptidomimetics show promise in modulating the aggregation pathways of critical amyloidogenic proteins.
- These agents can interfere with protein-protein interactions essential for fibril formation.
- The reviewed approaches demonstrate the versatility of peptidomimetics in targeting diverse amyloid proteins.
Conclusions:
- Peptidomimetic-based strategies offer a powerful platform for developing novel anti-amyloid therapeutic agents.
- This approach represents a significant step towards creating treatments for a range of irremediable amyloid diseases.
- Further research into peptidomimetics could lead to breakthrough therapies for neurodegenerative and other amyloid-associated conditions.
Related Concept Videos
03:03Amyloid Fibrils
9.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.7K
01:22Alzheimer's Disease: Treatment
246
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
246